Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21491292 | 0.87 | KDM4E (0.39) | CRHBPCRHR2SMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL29456443 | 0.87 | KDM4E (0.39) | CRHBPCRHR2SMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL24313515 | 0.86 | CRHBP (0.50) | CRHBPCRHR2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24313097 | 0.83 | CRHBP (0.47) | CRHBPCRHR2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24313458 | 0.81 | CRHBP (0.42) | CRHBPCRHR2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24313314 | 0.81 | CRHBP (0.45) | CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL21491330 | 0.80 | CRHBP (0.48) | CRHBPCRHR2SMN1; SMN2KDM4EHTT | |
| SCHEMBL21491331 | 0.80 | CRHBP (0.48) | CRHBPCRHR2SMN1; SMN2KDM4EHTT | |
| SCHEMBL21491441 | 0.80 | CRHBP (0.48) | CRHBPCRHR2SMN1; SMN2KDM4EHTT | |
| SCHEMBL29456542 | 0.80 | CRHBP (0.48) | CRHBPCRHR2SMN1; SMN2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-27 | — | — | US | disclosed |
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322658-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885 |
| US-10815225-B2 | Antiproliferation compounds and uses thereof | MKI67, MCL1, CCNI | CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.